TP037/#453 Up-next (GOG-3049/ENGOT-OV71-NSGO-CTU): a study of upifitamab rilsodotin (UPRI), a NaPi2b -directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer. (4th December 2022)

• Record Type: Journal Article
• Authors: Richardson, Debra; Harter, Philipp; O'Malley, David; Gonzalez-Martin, Antonio; Herzog, Thomas; Rogalski, Caroline; Burger, Robert; Mirza, Mansoor
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 3
• Page Start: A241
• Page End: A241
• Publication Date: 2022-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-igcs.546
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: UpRi is a first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables high drug-to-antibody ratio and controlled bystander effect. NaPi2b is a sodium-dependent phosphate transporter protein broadly expressed in high-grade serous ovarian cancer (HGSOC) with limited expression in healthy tissues. It's estimated that about two-thirds of HGSOC patients are NaPi2b-high. Studies are being conducted to evaluate UpRi safety and efficacy in platinum-resistant ovarian cancer (PROC), but there remains an unmet need in in the maintenance setting for patients with platinum-sensitive, recurrent ovarian cancer (PSOC), particularly patients who received standard-of-care treatment and are at high-risk of early relapse. Methods: UP-NEXT is a Ph3 study evaluating UpRi monotherapy as post-platinum maintenance therapy in recurrent PSOC, enrolling patients with NaPi2b-high tumors (defined as TPS ≥75). Patients must have received 2–4 prior lines of platinum containing chemotherapy, achieved a partial or complete response in their penultimate platinum regimen, and progressed >6mo after completion of the last dose of platinum. Patients may be enrolled if their best response to the last line of treatment is no evidence of disease, complete or partial response, or stable disease. If patients have a known BRCA mutation, prior PARPi treatment is required. Patients who received bevacizumab in combination with their last platinum containing regimen are excluded. Patients are randomized 2:1 to UpRi or placebo, given IV Q4W. The primary endpoint is PFS assessed by BICR, with key secondary endpoint of OS. UP-NEXT is conducted in collaboration with GOG(3049) and ENGOT(Ov71-NSGO-CTU) . ~350 patients will be enrolled globally. NCT05329545 Results: TrialinProgress Conclusions: TrialinProgress